systemic sclerosis and treatment options Archives

Abstract Number: 2673 • ACR/ARHP Annual Meeting 2017
Real-Life Treatment Strategies for Systemic Sclerosis According to Experts
Andreu Fernández-Codina^1,2, Kyle M Walker³ and Janet E. Pope⁴, ¹Rheumatology, University of Western Ontario, London, ON, Canada, ²Systemic Autoimmune Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Dept. of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁴University of Western Ontario, London, ON, Canada
Background/Purpose:Second line treatment options for Systemic Sclerosis (SSc) are limited, and scarce data are available for choosing the order of treatment. The aim of this…
Abstract Number: 1678 • ACR/ARHP Annual Meeting 2014
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Matthew R. Lammi¹, Lesley Ann Saketkoo², Stephen C. Mathai³, Robyn T. Domsic⁴, Christine M. Bojanowski⁵, Virginia D. Steen⁶, Daniel E. Furst⁷ and Pharos Investigators⁸, ¹Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Medicine, Johns Hopkins University, Baltimore, MD, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, ⁶Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁷University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁸Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…

Abstracts tagged "systemic sclerosis and treatment options"

Real-Life Treatment Strategies for Systemic Sclerosis According to Experts

Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort